Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer

British Journal of Cancer
M ReniA A Brandes

Abstract

Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients present good performance status (PS) and are candidate for further treatment. Patients >18 years, PS >or=50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) <12 months received a combination of raltitrexed (3 mg m(-2)) and oxaliplatin (130 mg m(-2)) every 3 weeks until progression, toxicity, or a maximum of six cycles. A total of 41 patients received 137 cycles of chemotherapy. Dose intensity for both drugs was 92% of the intended dose. Main grade >2 toxicity was: neutropenia in five patients (12%), thrombocytopenia, liver and vomiting in three (7%), fatigue in two (5%). In total, 10 patients (24%) yielded a partial response, 11 a stable disease. Progression-free survival at 6 months was 14.6%. Median survival was 5.2 months. Survival was significantly longer in patients with previous PFS >6 months and in patients without pancreatic localisation. A clinically relevant improvement of quality of life was observed in numerous domains. Raltitrexed-oxaliplatin regimen may constitute a treatment opportunity in ...Continue Reading

References

Jan 1, 1990·Cancer Investigation·J A AjaniI H Krakoff
Jun 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R LionettoR Rosso
Jan 1, 1996·Investigational New Drugs·R PazdurJ L Abbruzzese
Aug 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusC Svensson
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D OsobaJ Pater
Dec 3, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E RaymondE Cvitkovic
Oct 26, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D FitzsimmonsT Tihanyi
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K FizaziJ P Armand
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S R BramhallUNKNOWN Marimastat Pancreatic Cancer Study Group
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jordan D BerlinAl Bowen Benson
Aug 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-F SeitzJ-Y Douillard
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio M Rocha LimaLangdon L Miller

❮ Previous
Next ❯

Citations

Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian M WolpinCharles S Fuchs
Mar 8, 2014·World Journal of Gastroenterology : WJG·Evan J Walker, Andrew H Ko
Mar 2, 2010·Japanese Journal of Clinical Oncology·Akiko TodakaHideharu Tomita
Jul 27, 2010·Japanese Journal of Clinical Oncology·Takehito ShukuyaNozomu Machida
May 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O E RahmaT F Greten
Mar 12, 2011·Expert Opinion on Therapeutic Targets·Jiang LongMin Li
Sep 2, 2015·Expert Review of Anticancer Therapy·Concetta Elisa OnestiPaolo Marchetti
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Mar 1, 2010·Therapeutic Advances in Medical Oncology·Ben Lawrence, Michael Findlay
Jan 4, 2008·Cancer Chemotherapy and Pharmacology·M ReniS Grisanti
Apr 10, 2008·Cancer Chemotherapy and Pharmacology·Chigusa MorizaneEiichiro Suzuki
Apr 12, 2008·Expert Review of Anticancer Therapy·Andreas Hilbig, Helmut Oettle
Apr 3, 2015·Journal of Gastrointestinal Cancer·Sara De DossoPiercarlo Saletti
Feb 6, 2009·American Journal of Clinical Oncology·Anna NovarinoLibero Ciuffreda
Feb 18, 2011·Current Opinion in Supportive and Palliative Care·Robert N Whistance, Jane M Blazeby
Sep 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Ibrahim Vedat BayogluMustafa Oktay Tarhan
Dec 17, 2015·Cancer Chemotherapy and Pharmacology·Carmen BelliMichele Reni
Aug 12, 2014·Molecular Medicine Reports·Song XueHai-Yun Geng
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BoeckV Heinemann
Sep 18, 2009·Cancer Treatment Reviews·Ana CustodioEduardo Díaz-Rubio

❮ Previous
Next ❯

Software Mentioned

Statistica

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J FeliuOncopaz Cooperative Group Associated Hospitals
© 2021 Meta ULC. All rights reserved